Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Athena Summit: Boosting Your Agency
BOSTON, Massachusetts, Dec. 10 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:
* * *
Athena Summit: Boosting Your Agency
*
Embark on a transformative journey at our second Athena Summit in San Francisco unlike any before it. This full-day experience on December 10, 2025, will be hosted at the Silicon Valley Bank Experience Center.
This immersive day will bring together the brightest women leaders, visionaries, and changemakers to reimagine leadership, career journeys, and the future of work.
From the moment you arrive, you'll step into a curated journey
... Show Full Article
BOSTON, Massachusetts, Dec. 10 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:
* * *
Athena Summit: Boosting Your Agency
*
Embark on a transformative journey at our second Athena Summit in San Francisco unlike any before it. This full-day experience on December 10, 2025, will be hosted at the Silicon Valley Bank Experience Center.
This immersive day will bring together the brightest women leaders, visionaries, and changemakers to reimagine leadership, career journeys, and the future of work.
From the moment you arrive, you'll step into a curated journeydesigned to expand your thinking, grow your network, and help you shape your Portfolio of Impact(tm).
* Athena's Wisdom Stage: Engage with inspiring keynote presentations and panels featuring thought leaders who will challenge your perspectives on leadership, purpose, and the evolving "why" of work.
* Immersive Interactives: Dive into intimate workshops and discussions in smaller breakout spaces like The Speak Easy and The Wise Owl Vault, where you'll re-envision your career trajectory and explore the power of transitions.
* The Weak Ties Challenge: Build meaningful new connections through structured conversations designed to spark collaboration and opportunity.
* Networking and Connection: Share space with executives, board directors, innovators, and fellow Athena members women who are actively shaping the future.
This Athena Summit is more than an event; it's a catalysta full-day immersive experience designed to challenge your thinking and expand your perspective. You'll leave with fresh insights, meaningful connections, and practical frameworks to navigate your leadership journey with impact.
Goodwin's Mary O'Carroll to be speaking on the "AI as a Teammate" panel, and Mitzi Chang will be speaking on "Trends in Governance."
Space is limited, with priority access for Athena members. The deadline to RSVP is November 25th. Reserve your spot today and start planning your trip if you'll be joining us from out of town.
***
Original text here: https://www.goodwinlaw.com/en/news-and-events/events/2025/12/technology-dpc-athena-summit-boosting-your-agency
Lee Health: Chronic Disease Self-Management Program "It's All About You"
FORT MYERS, Florida, Dec. 6 -- Lee Health issued the following news release:
* * *
Chronic Disease Self-Management Program "It's All About You"
Lee Health's "It's All About You," Chronic Disease Self-Management Program" a Self- Management Resource Program with the SMRC is offering two research based Chronic Disease Self-Management programs for the community.
The program is designed for people 18 years of age or older with chronic health conditions to help them learn ways to better manage their chronic conditions and the symptoms that often accompany chronic health conditions. Participants
... Show Full Article
FORT MYERS, Florida, Dec. 6 -- Lee Health issued the following news release:
* * *
Chronic Disease Self-Management Program "It's All About You"
Lee Health's "It's All About You," Chronic Disease Self-Management Program" a Self- Management Resource Program with the SMRC is offering two research based Chronic Disease Self-Management programs for the community.
The program is designed for people 18 years of age or older with chronic health conditions to help them learn ways to better manage their chronic conditions and the symptoms that often accompany chronic health conditions. Participantswill receive a complimentary copy of the book, "Living a Healthier Life with Chronic Conditions."
The in-person workshops are held once a week for 6 weeks and they are FREE.
Workshops will be offered on:
Tuesdays beginning Jan. 6, from 9:30 a.m. - 12 p.m. at the Gateway Trinity Lutheran Church, 11381 Gateway Blvd., Fort Myers.
Thursdays beginning Jan. 8, from 9:30 a.m. - 12 p.m. at the Healthy Life Center, 23450 Via Coconut Point, Estero.
For more information or to register, please call 239-424-3121.
* * *
Original text here: https://www.leehealth.org/about-us/media/press-releases/chronic-disease-self-management-program-it-s-21
[Category: BizHealth Care]
Johnson & Johnson's INLEXZO Delivers 74 Percent Disease-Free Survival at One Year in BCG-Unresponsive, High-Risk, Papillary-Only NMIBC
RARITAN, New Jersey, Dec. 6 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson's INLEXZO(TM) (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal
Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies
... Show Full Article
RARITAN, New Jersey, Dec. 6 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson's INLEXZO(TM) (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal
Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapiesfor bladder preservation
*
Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC)./1 These data were featured as a late-breaking oral presentation at the Society of Urologic Oncology (SUO) 2025 Annual Meeting and build upon data presented at the 2025 American Urological Association (AUA) Annual Meeting.
"The findings are meaningful, as the majority of patients remained free of cancer recurrence at one year despite having papillary tumors that carry a high risk for recurrence and a significant risk of progression to a more aggressive, muscle-invasive stage of disease," said Siamak Daneshmand*, M.D., Professor of Urology, University of Southern California, and presenting author. "Bladder removal has traditionally been the primary path forward for these patients, a life-altering procedure that can have a significant impact on a patient's quality of life."
"At Johnson & Johnson, we are committed to developing innovative treatments for patients with high-risk NMIBC who have few options beyond life-altering surgery," said Christopher Cutie, M.D., Vice President, Disease Area Leader, Bladder Cancer, Johnson & Johnson Innovative Medicine. "Those with papillary-only disease face particularly difficult decisions, as surgical removal of the bladder has long been the standard of care for patients who are unresponsive or resistant to BCG."
Cohort 4 of the Phase 2b SunRISe-1 study focused on 52 patients with papillary-only, high-risk NMIBC whose disease did not respond or stopped responding to BCG therapy and who were ineligible for or declined radical cystectomy. The therapy was administered every three weeks for six months, followed by every 12 weeks for up to an additional 18 months, to evaluate its potential to prevent the recurrence or progression of high-grade papillary tumors.1 The results support continued evaluation in the ongoing Phase 3 SunRISe-5 study (NCT06211764) comparing gemcitabine intravesical system to chemotherapy in patients with previously BCG-treated, papillary-only NMIBC.
At median follow-up of 15.9 months (range, 4-20 months), the one-year DFS rate was 74.3 percent (95 percent confidence interval [CI], 59.2-84.6), meaning nearly three out of four patients remained free from cancer recurrence. Results were similar across patients with high-grade Ta and T1 papillary tumors, 74.8 percent and 74.1 percent, respectively (95 percent CI, 54.3-87.1 and 48.5-88.3). At one year, PFS was 95.6 percent (95 percent CI, 83.5-98.9) and OS was 98 percent (95 percent CI, 86.6-99.7). Notably, 92.3 percent of patients did not undergo radical cystectomy, and median time to cystectomy was not reached. Overall Health Status and Physical Functioning scores were maintained during treatment with gemcitabine intravesical system./1
The therapy was generally well-tolerated. Most patients (80.8 percent) experienced treatment-related side effects that were low grade, such as mild urinary symptoms, including burning, frequency, or urgency. More serious side effects (13.5 percent) were uncommon and most often involved bladder pain. A small number of patients (7.7 percent) discontinued treatment due to side effects, and no treatment-related deaths were reported./1
About SunRISe-1, Cohort 4
SunRISe-1 (NCT04640623) is an ongoing Phase 2b, open-label, multicenter study evaluating the efficacy and safety of gemcitabine intravesical system in patients with BCG-unresponsive HR-NMIBC who are ineligible for, or elected not to undergo, radical cystectomy. Cohort 4 specifically enrolls patients with papillary-only disease. The primary endpoint of Cohort 4 is disease-free survival (DFS) rate at 12 months. Key secondary endpoints included safety and tolerability./2
About High-Risk Non-Muscle Invasive Bladder Cancer
High-risk non-muscle invasive bladder cancer is a type of non-invasive bladder cancer that is more likely to recur or spread beyond the lining of the bladder, called the urothelium, and progress to muscle invasive bladder cancer compared to low-risk NMIBC./3,4 HR-NMIBC makes up 15-44 percent of patients with NMIBC and is characterized by a high-grade, large tumor size, presence of multiple tumors, and carcinoma in situ.5 Radical cystectomy is currently recommended for HR-NMIBC patients who fail BCG therapy, with over 90 percent cancer-specific survival if performed before muscle-invasive progression.6,7 Given that NMIBC typically affects older patients, many may be unwilling or unfit to undergo radical cystectomy.8 The high rates of recurrence and progression can pose significant morbidity and distress for these patients./3,4
About INLEXZO(TM) (gemcitabine intravesical system)
INLEXZO(TM) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
The safety and efficacy of INLEXZO(TM) is being evaluated in clinical trials in patients with MIBC in SunRISe-4, and HR-NMIBC in SunRISe-1, SunRISe-3, and SunRISe-5.
The legal manufacturer for INLEXZO(TM) is Janssen Biotech, Inc.
INLEXZO(TM) IMPORTANT SAFETY INFORMATION9
CONTRAINDICATIONS
INLEXZO(TM) is contraindicated in patients with:
Perforation of the bladder.
Prior hypersensitivity reactions to gemcitabine or any component of the product.
WARNINGS AND PRECAUTIONS
Risks in Patients with Perforated Bladder
INLEXZO(TM) may lead to systemic exposure to gemcitabine and to severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised.
Evaluate the bladder before the intravesical administration of INLEXZO(TM) and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.
Risk of Metastatic Bladder Cancer with Delayed Cystectomy
Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. The risk of developing muscle invasive or metastatic bladder cancer increases the longer cystectomy is delayed in the presence of persisting CIS.
Of the 83 evaluable patients with BCG-unresponsive CIS treated with INLEXZO(TM) in Cohort 2 of SunRISe-1, 7 patients (8%) progressed to muscle invasive (T2 or greater) bladder cancer. Three patients (3.5%) had progression determined at the time of cystectomy. The median time between determination of persistent or recurrent CIS or T1 and progression to muscle invasive disease was 94 days.
Magnetic Resonance Imaging (MRI) Safety
INLEXZO(TM) can only be safely scanned with MRI under certain conditions. Refer to section 5.3 of the USPI for details on conditions.
Embryo-Fetal Toxicity
Based on animal data and its mechanism of action, INLEXZO(TM) can cause fetal harm when administered to a pregnant woman if systemic exposure occurs. In animal reproduction studies, systemic administration of gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits.
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after final removal of INLEXZO(TM). Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after final removal of INLEXZO(TM).
ADVERSE REACTIONS
Serious adverse reactions occurred in 24% of patients receiving INLEXZO(TM). Serious adverse reactions that occurred in >2% of patients included urinary tract infection, hematuria, pneumonia, and urinary tract pain. Fatal adverse reactions occurred in 1.2% of patients who received INLEXZO(TM), including cognitive disorder.
The most common (>15%) adverse reactions, including laboratory abnormalities, were urinary frequency, urinary tract infection, dysuria, micturition urgency, decreased hemoglobin, increased lipase, urinary tract pain, decreased lymphocytes, hematuria, increased creatinine, increased potassium, increased AST, decreased sodium, bladder irritation, and increased ALT.
USE IN SPECIFIC POPULATIONS
Pregnancy
There are no available data on the use of INLEXZO(TM) in pregnant women to inform a drug-associated risk.
Please see Embryo-Fetal Toxicity for risk information related to pregnancy.
Lactation
Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 week after final removal of INLEXZO(TM).
Females and Males of Reproductive Potential
Pregnancy Testing - Verify pregnancy status in females of reproductive potential prior to initiating INLEXZO(TM).
Contraception - Please see Embryo-Fetal Toxicity for information regarding contraception.
Infertility (Males) - Based on animal studies, INLEXZO(TM) may impair fertility in males of reproductive potential. It is not known whether these effects on fertility are reversible.
Geriatric Use
Of the patients given INLEXZO(TM) monotherapy in Cohort 2 of SunRISe-1, 72% were 65 years of age or older and 34% were 75 years or older. There were insufficient numbers of patients <65 years of age to determine if these patients respond differently to patients 65 years of age and older.
Please read full Prescribing Information (https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INLEXZO-pi.pdf) and Instructions for Use for INLEXZO(TM).
* * *
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
* * *
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of INLEXZO(TM). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
* * *
Footnotes
*/ Dr. Siamak Daneshmand has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work.
1/ Daneshmand, S., & colleagues. (2025). Gemcitabine intravesical system (TAR-200) monotherapy in patients with Bacillus Calmette-Guerin-unresponsive papillary disease-only high-risk non-muscle-invasive bladder cancer: 1-year disease-free survival results from SUNRISE-1. Abstract presented at the Society of Urologic Oncology (SUO) Annual Meeting.
2/ ClinicalTrials.gov. A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1). https://clinicaltrials.gov/study/NCT04640623. Accessed December 2025.
3/ Grab-Heyne K, Henne C, Mariappan P, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124.
4/ Lieblich A, Henne C, Mariappan P, Geiges G, Pohlmann J, Pollock RF. The management of non-muscle-invasive bladder cancer: a comparison of European and UK guidelines. J Clin Urol. 2018;11(2):144-148.
5/ Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94. doi:10.1016/j.eururo.2021.08.010
6/ Brooks NA, O'Donnell MA. Treatment options in non-muscle-invasive bladder cancer after BCG failure. Indian J Urol. 2015;31(4):312-319. doi:10.4103/0970-1591.166475
7/ Guancial EA, Roussel B, Bergsma DP, et al. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging. 2015;10:939-949.
8/ Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: A population-based analysis. Cancer. 2013;119(17):3219-3227.
9/ INLEXZO(TM) U.S. Prescribing Information.
* * *
Original text here: https://www.jnj.com/media-center/press-releases/johnson-johnsons-inlexzo-gemcitabine-intravesical-system-delivers-74-percent-disease-free-survival-at-one-year-in-bcg-unresponsive-high-risk-papillary-only-nmibc
[Category: BizPharmaceuticals]
IHeartPodcasts Announces 'An Unlikely Affair,' The First Series To Debut Under Lala Kent's And IHeart's New Expanded Podcast Slate
SAN ANTONIO, Texas, Dec. 6 [Category: BizMedia] -- iHeartMedia issued the following news release on Dec. 5, 2025:
* * *
iHeartPodcasts Announces "An Unlikely Affair," The First Series To Debut Under Lala Kent's And iHeart's New Expanded Podcast Slate
A spinoff of Lala Kent's "Untraditionally Lala," the new series cohosted by Kent and Ambyr Childers follows the two former adversaries who
unexpectedly became bonded single mothers
Premiere episode set to debut on January 8, 2026
*
LOS ANGELES - iHeartPodcasts, the No. 1 podcast publisher globally according to Podtrac, today announced the launch
... Show Full Article
SAN ANTONIO, Texas, Dec. 6 [Category: BizMedia] -- iHeartMedia issued the following news release on Dec. 5, 2025:
* * *
iHeartPodcasts Announces "An Unlikely Affair," The First Series To Debut Under Lala Kent's And iHeart's New Expanded Podcast Slate
A spinoff of Lala Kent's "Untraditionally Lala," the new series cohosted by Kent and Ambyr Childers follows the two former adversaries who
unexpectedly became bonded single mothers
Premiere episode set to debut on January 8, 2026
*
LOS ANGELES - iHeartPodcasts, the No. 1 podcast publisher globally according to Podtrac, today announced the launchof "An Unlikely Affair," the first official series under Lala Kent's new "Untraditionally Lala" umbrella, a growing podcast slate that will expand within iHeart's Popworthy lineup of shows. Hosted by reality TV star and entrepreneur Lala Kent alongside actress and producer Ambyr Childers, who's best known for her roles in "You" and "Ray Donovan," the new series will build on the success of Kent's previously launched podcast "Untraditionally Lala," where Childers made her first appearance earlier this year. "An Unlikely Affair" premieres on January 8, 2026, with the official trailer available now, HERE.
Each week on "An Unlikely Affair," Lala and Ambyr dive into the realities single mothers face, drawing from a past that once made them sworn enemies after sharing the same ex. In a twist no one saw coming, the two have let go of their history and built an unexpected, deeply honest
friendship. Together, they explore how to navigate major transitions, manage mom guilt while reclaiming their identities, and approach dating and sex in their next chapter. The cohosts share how they reclaimed their happiness and hope their journey inspires listeners to let go of toxicity and rewrite their own narratives.
Kent will continue to host "Untraditionally Lala" with episodes dropping every Wednesday, and bonus content released on Mondays.
"An Unlikely Affair" is distributed by iHeartPodcasts as part of its Popworthy slate, where trending culture and nostalgia intersect. Listen on the iHeartRadio app and everywhere podcasts are heard.
Follow @lalakent, @ambyrchilders_official and @anunlikelyaffair on Instagram for podcast clips and updates on the podcast.
Follow all Popworthy shows @popworthypodcasts.
* * *
About iHeartMedia, Inc.
iHeartMedia, Inc. [Nasdaq: IHRT] is the leading audio media company in America, with nine out of ten Americans listening to iHeart broadcast radio in every month. iHeart's broadcast radio assets alone have a larger audience in the U.S. than any other media outlet; twice the size of the next largest broadcast radio company; and over four times the ad-enabled audience of the largest digital only audio service. iHeart is the largest podcast publisher according to Podtrac, with more downloads than the next two podcast publishers combined, has the most recognizable live events across all genres of music, has the number one social footprint among audio players, with five times more followers than the next audio media brand, and is the only fully integrated audio ad tech solution across broadcast, streaming and podcasts. The company continues to leverage its strong audience connection and unparalleled consumer reach to build new platforms, products and services. Visit iHeartMedia.com for more company information.
* * *
Original text here: https://www.iheartmedia.com/press/iheartpodcasts-announces-unlikely-affair-first-series-debut-under-lala-kents-and-ihearts-new
Hanson Bridgett: Kristina Lawson Joins Daily Journal Podcast
SAN FRANCISCO, California, Dec. 6 -- Hanson Bridgett, a law firm, issued the following news release:
* * *
Kristina Lawson Joins Daily Journal Podcast
Kristina Lawson recently joined the Daily Journal's In the Counsel's Chair podcast to discuss her path from serving as a Walnut Creek city councilmember and mayor to leading a statewide firm. She shares how public service continues to influence her leadership, offers guidance for attorneys considering public roles, and reflects on what Hanson Bridgett's expanded footprint means for clients and communities.
"We have an all-California strategy,
... Show Full Article
SAN FRANCISCO, California, Dec. 6 -- Hanson Bridgett, a law firm, issued the following news release:
* * *
Kristina Lawson Joins Daily Journal Podcast
Kristina Lawson recently joined the Daily Journal's In the Counsel's Chair podcast to discuss her path from serving as a Walnut Creek city councilmember and mayor to leading a statewide firm. She shares how public service continues to influence her leadership, offers guidance for attorneys considering public roles, and reflects on what Hanson Bridgett's expanded footprint means for clients and communities.
"We have an all-California strategy,and it was really incredible to see that come to life this year," said Managing Partner Kristina Lawson, reflecting on Hanson Bridgett's expansion into San Diego and Fresno. "By doing that, we're now in every major market in California, and we're really excited about what that means for the future of Hanson Bridgett and our ability to serve clients."
* * *
Kristina Lawson, Managing Partner, San Francisco, CA
* * *
Original text here: https://www.hansonbridgett.com/news/kristina-lawson-joins-daily-journal-podcast
[Category: BizLaw/Legal]
Attorney Anna Long Publishes Article Spotlighting Stormwater Rules Effective December 28, 2025
ORLANDO, Florida, Dec. 6 -- Dean Mead, a law firm, issued the following news release:
* * *
Attorney Anna Long Publishes Article Spotlighting Stormwater Rules Effective December 28, 2025
(Orlando, FL) Dean Mead Real Estate attorney Anna Long has published, "Rising Standards. Rising Stakes: Understanding Florida's Updated Stormwater Rules." In the article Anna highlights the impact of Florida Senate Bill 7040: Ratification of the Department of Environmental Protection's Rules Relating to Stormwater, with a focus on water management districts, and property owners and developers.
The author writes,
... Show Full Article
ORLANDO, Florida, Dec. 6 -- Dean Mead, a law firm, issued the following news release:
* * *
Attorney Anna Long Publishes Article Spotlighting Stormwater Rules Effective December 28, 2025
(Orlando, FL) Dean Mead Real Estate attorney Anna Long has published, "Rising Standards. Rising Stakes: Understanding Florida's Updated Stormwater Rules." In the article Anna highlights the impact of Florida Senate Bill 7040: Ratification of the Department of Environmental Protection's Rules Relating to Stormwater, with a focus on water management districts, and property owners and developers.
The author writes,"Beginning December 28, 2025, new statewide stormwater management rules will ... [impact] how public agencies, businesses, and private landowners approach development and redevelopment projects. This shift could increase both design complexity and project budgets."
To read the article in its entirety visit: https://www.deanmead.com/rising-standards-rising-stakes-understanding-floridas-updated-stormwater-rules/.
* * *
Original text here: https://www.deanmead.com/attorney-anna-long-publishes-article-spotlighting-stormwater-rules-effective-december-28-2025/
[Category: BizLaw/Legal]
Super-Midsize Gulfstream G300 Takes Flight
SAVANNAH, Georgia, Dec. 6 -- Gulfstream Aerospace, a subsidiary of General Dynamics, issued the following news release on Dec. 5, 2025:
* * *
Super-Midsize Gulfstream G300 Takes Flight
Milestone Officially Launches Flight Test Program, Demonstrates Significant Program Maturity
*
Gulfstream Aerospace Corp. today announced the new Gulfstream G300 has made its first flight, demonstrating significant program maturity and officially launching its rigorous flight test program. Introduced on Sept. 30 in Savannah as the latest addition to Gulfstream's visionary fleet, the G300 represents a new standard
... Show Full Article
SAVANNAH, Georgia, Dec. 6 -- Gulfstream Aerospace, a subsidiary of General Dynamics, issued the following news release on Dec. 5, 2025:
* * *
Super-Midsize Gulfstream G300 Takes Flight
Milestone Officially Launches Flight Test Program, Demonstrates Significant Program Maturity
*
Gulfstream Aerospace Corp. today announced the new Gulfstream G300 has made its first flight, demonstrating significant program maturity and officially launching its rigorous flight test program. Introduced on Sept. 30 in Savannah as the latest addition to Gulfstream's visionary fleet, the G300 represents a new standardin its segment and is poised to redefine the super-midsize category.
The first G300 took off from Ben Gurion International Airport at 8:05 a.m. local time and flew for 2 hours and 25 minutes at a speed of Mach 0.75 and an altitude of 30,000 feet/9,144 meters.
"With its combination of safety, technology, performance and cabin comfort, the G300 is a game changer for the super-midsize category," said Mark Burns, president, Gulfstream. "This latest investment, designed to exceed our customers' expectations for large-cabin features in a mid-cabin aircraft, brings another new category leader to our next-generation fleet. With the addition of the G300, Gulfstream truly offers an aircraft for every mission. Achieving first flight at this stage in the program is a remarkable achievement."
The G300 features the largest interior in the super-midsize segment. Natural light from 10 Gulfstream Panoramic Oval Windows enhances the spacious cabin, which can seat up to 10 passengers and includes two living areas, a generously appointed galley and ample room for baggage. The G300 also features the lowest cabin altitude in its class at 4,800 ft/1,463 m when flying at 41,000 ft/12,497 m, along with 100% fresh air, a standard plasma air ionization system and whisper-quiet sound levels.
The G300 boasts class-leading range at the highest speeds with the ability to fly 3,600 nautical miles/6,667 kilometers at Mach 0.80 or 3,000 nm/5,556 km at Mach 0.84. In addition, the aircraft also features impressive fuel-efficiency thanks to its combination of the clean, swept Gulfstream wing and Honeywell HTF7250G engines.
With next-generation technology, the G300 Harmony Flight Deck greatly enhances safety with six touch screens paired with Phase-of-Flight intelligence, a Synthetic Vision-Primary Flight Display that depicts runways and terrain in 3D imagery, and Gulfstream's award-winning Predictive Landing Performance System.
Prior to first flight, the G300 program completed more than 2,000 ground test hours and includes two additional test aircraft already in production.
* * *
NOTE TO EDITORS
Inspired by the belief that aviation could fuel business growth, Gulfstream Aerospace Corp. invented the first purpose-built business aircraft, the Gulfstream I, which first flew in 1958. Today, more than 3,400 aircraft are in service around the world. Together with parent company General Dynamics, Gulfstream consistently invests in the future, dedicating resources to researching and developing innovative new aircraft, technologies and services. Gulfstream's next-generation family of aircraft, including the super-midsize Gulfstream G300, the category-leading Gulfstream G400, the award-winning Gulfstream G500 and Gulfstream G600, the ultralarge-cabin Gulfstream G700 and the ultralong-range Gulfstream G800, offers an aircraft for every mission. All are backed by the worldwide Gulfstream Customer Support network. Learn more at gulfstream.com.
More information about General Dynamics is available at generaldynamics.com.
* * *
Original text here: https://www.gulfstreamnews.com/en/news/?id=55bfee51-8201-44be-ab85-b4310f21a900
[Category: BizAerospace]
